Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Celine Goldberger

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Journal of Affective Disorders|October 15, 2009
Relationship between TSH levels in the normal range and short-term duloxetine efficacyEmmanuelle Corruble, Celine Goldberger, Melissa Spann
Journal of Clinical Psychopharmacology|March 28, 2015
Long-Term, Open-Label, Safety Study of Edivoxetine 12 to 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor TreatmentSusan G Ball, Sarah Atkinson, JonDavid Sparks, et al.
Journal of Psychiatric Research|April 23, 2011
A randomized, double-blind study comparing LY2216684 and placebo in the treatment of major depressive disorderBeth Pangallo, Mary Anne Dellva, Deborah N D'Souza, et al.
Neuroreport|August 2, 2005
Age at onset of schizophrenia: interaction between brain-derived neurotrophic factor and dopamine D3 receptor gene variantsDavid Gourion, Celine Goldberger, Sophie Leroy, et al.
Journal of Affective Disorders|July 5, 2014
A double-blind, placebo-controlled study of edivoxetine as an adjunctive treatment for patients with major depressive disorder who are partial responders to selective serotonin reuptake inhibitor treatmentSusan Ball, Mary Anne Dellva, Deborah N D'Souza, et al.
The Journal of Clinical Psychiatry|September 30, 2016
Is the Noradrenergic Symptom Cluster a Valid Construct in Adjunctive Treatment of Major Depressive Disorder?Virginia L Stauffer, Peng Liu, Celine Goldberger, et al.
Current Medical Research and Opinion|April 21, 2015
Edivoxetine compared to placebo as adjunctive therapy to selective serotonin reuptake inhibitors in the prevention of symptom re-emergence in major depressive disorderTina M Oakes, Mary Anne Dellva, Karen Waterman, et al.
Drugs in Context|May 26, 2015
Safety and tolerability of edivoxetine as adjunctive treatment to selective serotonin reuptake inhibitor antidepressants for patients with major depressive disorderJames M Martinez, Margaret B Ferguson, Beth A Pangallo, et al.
The Journal of Clinical Psychiatry|April 2, 2016
Efficacy outcomes from 3 clinical trials of edivoxetine as adjunctive treatment for patients with major depressive disorder who are partial responders to selective serotonin reuptake inhibitor treatmentSusan G Ball, Margaret B Ferguson, James M Martinez, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Journal of Affective Disorders|October 15, 2009
Relationship between TSH levels in the normal range and short-term duloxetine efficacyEmmanuelle Corruble, Celine Goldberger, Melissa Spann
Journal of Clinical Psychopharmacology|March 28, 2015
Long-Term, Open-Label, Safety Study of Edivoxetine 12 to 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor TreatmentSusan G Ball, Sarah Atkinson, JonDavid Sparks, et al.
Journal of Psychiatric Research|April 23, 2011
A randomized, double-blind study comparing LY2216684 and placebo in the treatment of major depressive disorderBeth Pangallo, Mary Anne Dellva, Deborah N D'Souza, et al.
Neuroreport|August 2, 2005
Age at onset of schizophrenia: interaction between brain-derived neurotrophic factor and dopamine D3 receptor gene variantsDavid Gourion, Celine Goldberger, Sophie Leroy, et al.
Journal of Affective Disorders|July 5, 2014
A double-blind, placebo-controlled study of edivoxetine as an adjunctive treatment for patients with major depressive disorder who are partial responders to selective serotonin reuptake inhibitor treatmentSusan Ball, Mary Anne Dellva, Deborah N D'Souza, et al.
The Journal of Clinical Psychiatry|September 30, 2016
Is the Noradrenergic Symptom Cluster a Valid Construct in Adjunctive Treatment of Major Depressive Disorder?Virginia L Stauffer, Peng Liu, Celine Goldberger, et al.
Current Medical Research and Opinion|April 21, 2015
Edivoxetine compared to placebo as adjunctive therapy to selective serotonin reuptake inhibitors in the prevention of symptom re-emergence in major depressive disorderTina M Oakes, Mary Anne Dellva, Karen Waterman, et al.
Drugs in Context|May 26, 2015
Safety and tolerability of edivoxetine as adjunctive treatment to selective serotonin reuptake inhibitor antidepressants for patients with major depressive disorderJames M Martinez, Margaret B Ferguson, Beth A Pangallo, et al.
The Journal of Clinical Psychiatry|April 2, 2016
Efficacy outcomes from 3 clinical trials of edivoxetine as adjunctive treatment for patients with major depressive disorder who are partial responders to selective serotonin reuptake inhibitor treatmentSusan G Ball, Margaret B Ferguson, James M Martinez, et al.
Pageof 1